Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PharmAla inks contract with Ostfold Hospital Trust in Oslo to supply clinical trial in exchange for both cash and a data license
-
- First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of chemotherapy in HER2-positive metastatic breast cancer; interim...
-
Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist,...
-
Transpire Bio CEO Dr. Xian-Ming Zeng will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026
-
Boehringer Ingelheim exercises option to license additional Dark Antigens from a wider array of tumor types, expanding Enara’s eligibility for milestone payments under existing collaboration Scott...
-
VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina”), a biopharmaceutical company advancing innovative cancer therapies...
-
Freiburg im Breisgau, Germany – January 8, 2026 – Eleva, a pioneer in discovering and developing previously inaccessible biologics, today announced the appointment of Dr. Erich Rajkovic, MBA, as Chief...
-
Alumis Announces Pricing of Upsized Public Offering of Common Stock
-
LOS ANGELES, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for...
-
Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market...